Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07264283 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

StatusEnrolling by Invitation
PhasePhase 2
SponsorAdam Boxer
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrolling by invitation only
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 30, 2026 to Jul 29, 2026
    v3
  2. Primary and study completion dates: Jul 31, 2029 to Sep 28, 2030
    • Start date: Dec 1, 2025 to Jun 30, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen B will evaluate the safety and efficacy of a single study drug, LM11A-31, in participants with PSP.
Trial Details
NCT Number NCT07264283
Lead Sponsor Adam Boxer
Collaborators: National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, University of Southern California, Massachusetts General Hospital, University of California, San Diego, Alzheimer's Clinical Trials Consortium, PharmatrophiX Inc.
Conditions
(from sponsor)		 PSP - Progressive Supranuclear Palsy
Related terms Frontotemporal Dementia, Supranuclear Palsy, Progressive
Enrollment 147 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov